Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:orphan drug
go back to main search page
Accession:CHEBI:71031 term browser browse the term
Definition:Any drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease.
Synonyms:related_synonym: orphan drugs
 xref: PMID:20036435;   PMID:20800761;   PMID:21180460;   PMID:21682893;   PMID:21947805;   PMID:22363762;   PMID:22366309;   PMID:22371464;   PMID:22731105;   PMID:22739138;   PMID:22747423;   PMID:22814659;   PMID:22814660;   PMID:22973866;   PMID:22981668;   PMID:22989856;   PMID:23013790;   PMID:23090701;   PMID:23109143;   PMID:23129684;   Wikipedia:Orphan_drug



show annotations for term's descendants           Sort by:
4-aminopyridine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adra1b adrenoceptor alpha 1B multiple interactions EXP 4-Aminopyridine inhibits the reaction [ADRA1B protein results in increased susceptibility to Phenylephrine] CTD PMID:18480251 NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP 4-Aminopyridine results in increased expression of BAX mRNA CTD PMID:24378259 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression EXP 4-Aminopyridine results in decreased expression of BIRC2 mRNA CTD PMID:24378259 NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression EXP 4-Aminopyridine results in decreased expression of BIRC3 mRNA CTD PMID:24378259 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Bmf Bcl2 modifying factor increases expression EXP 4-Aminopyridine results in increased expression of BMF mRNA CTD PMID:24378259 NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
JBrowse link
G C5h1orf159 similar to human chromosome 1 open reading frame 159 increases expression EXP 4-Aminopyridine results in increased expression of C1ORF159 mRNA CTD PMID:24378259 NCBI chr 5:166,701,485...166,719,939
Ensembl chr 5:166,701,676...166,719,955
JBrowse link
G Casp3 caspase 3 increases activity EXP 4-Aminopyridine results in increased activity of CASP3 protein CTD PMID:24378259 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 increases activity EXP 4-Aminopyridine results in increased activity of CASP7 protein CTD PMID:24378259 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp9 caspase 9 increases activity EXP 4-Aminopyridine results in increased activity of CASP9 protein CTD PMID:24378259 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cd40 CD40 molecule increases expression EXP 4-Aminopyridine results in increased expression of CD40 mRNA CTD PMID:24378259 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cd40lg CD40 ligand increases expression EXP 4-Aminopyridine results in increased expression of CD40LG mRNA CTD PMID:24378259 NCBI chr  X:135,127,052...135,138,768
Ensembl chr  X:135,126,969...135,138,306
JBrowse link
G Ctsb cathepsin B increases expression EXP 4-Aminopyridine results in increased expression of CTSB mRNA CTD PMID:24378259 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Dpysl4 dihydropyrimidinase-like 4 increases expression EXP 4-Aminopyridine results in increased expression of DPYSL4 mRNA CTD PMID:24378259 NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
JBrowse link
G Gad2 glutamate decarboxylase 2 increases expression
multiple interactions
EXP 4-Aminopyridine results in increased expression of GAD2 mRNA
KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA]
CTD PMID:25917026 NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
JBrowse link
G Galnt5 polypeptide N-acetylgalactosaminyltransferase 5 decreases expression EXP 4-Aminopyridine results in decreased expression of GALNT5 mRNA CTD PMID:24378259 NCBI chr 3:42,573,622...42,619,881
Ensembl chr 3:42,573,622...42,619,881
JBrowse link
G Grin2d glutamate ionotropic receptor NMDA type subunit 2D multiple interactions ISO [Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein CTD PMID:19911010 NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
JBrowse link
G Hdac5 histone deacetylase 5 multiple interactions EXP [Bicuculline co-treated with 4-Aminopyridine] affects the localization of HDAC5 protein CTD PMID:15773917 NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
JBrowse link
G Jph3 junctophilin 3 increases expression EXP 4-Aminopyridine results in increased expression of JPH3 mRNA CTD PMID:24378259 NCBI chr19:49,793,967...49,855,338
Ensembl chr19:49,793,092...49,855,338
JBrowse link
G Kcna10 potassium voltage-gated channel subfamily A member 10 multiple interactions ISO 4-Aminopyridine inhibits the reaction [KCNA10 protein results in increased transport of Potassium] CTD PMID:10836990 NCBI chr 2:194,786,500...194,798,575
Ensembl chr 2:194,786,500...194,798,575
JBrowse link
G Kcnd3 potassium voltage-gated channel subfamily D member 3 increases expression
multiple interactions
EXP 4-Aminopyridine results in increased expression of KCND3 mRNA
KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA]
CTD PMID:25917026 NCBI chr 2:192,937,950...193,155,345
Ensembl chr 2:192,937,950...193,155,345
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO 4-Aminopyridine results in decreased activity of KCNH2 protein CTD PMID:19915712 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
JBrowse link
G Kcnip1 potassium voltage-gated channel interacting protein 1 decreases expression
increases expression
multiple interactions
EXP 4-Aminopyridine results in decreased expression of KCNIP1 mRNA
4-Aminopyridine results in increased expression of KCNIP1 mRNA
KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased abundance of gamma-Aminobutyric Acid]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA]
CTD PMID:24378259 PMID:25917026 NCBI chr10:18,219,519...18,588,833
Ensembl chr10:18,219,519...18,589,045
JBrowse link
G Kcnn4 potassium calcium-activated channel subfamily N member 4 decreases expression ISO 4-aminopyridine decreases expression of KCNN4 mRNA and protein in CD4-positive alpha-beta T cell RGD PMID:26502942 RGD:329955577 NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
JBrowse link
G Mag myelin-associated glycoprotein decreases expression EXP 4-Aminopyridine results in decreased expression of MAG mRNA CTD PMID:24378259 NCBI chr 1:86,148,227...86,163,726
Ensembl chr 1:86,148,228...86,163,656
JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha increases expression EXP 4-Aminopyridine results in increased expression of MAP1LC3A mRNA CTD PMID:24378259 NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO
EXP
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein]
4-Aminopyridine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein]
CTD PMID:19911010 PMID:22759588 PMID:28132918 PMID:33621091 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein]
4-Aminopyridine results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein]
CTD PMID:19911010 PMID:22759588 PMID:28132918 PMID:33621091 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Ncor2 nuclear receptor co-repressor 2 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein] CTD PMID:15773917 NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha increases phosphorylation
multiple interactions
EXP 4-Aminopyridine results in increased phosphorylation of PRKACA protein
lappaconitine inhibits the reaction [4-Aminopyridine results in increased phosphorylation of PRKACA protein]
CTD PMID:35643327 NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions EXP [Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]] CTD PMID:15773917 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
JBrowse link
G S100a7a S100 calcium binding protein A7A decreases expression EXP 4-Aminopyridine results in decreased expression of S100A7A mRNA CTD PMID:24378259 NCBI chr 2:176,151,405...176,155,846
Ensembl chr 2:176,151,288...176,156,441
JBrowse link
G Snap25 synaptosome associated protein 25 multiple interactions
increases phosphorylation
EXP lappaconitine inhibits the reaction [4-Aminopyridine results in increased phosphorylation of SNAP25 protein] CTD PMID:35643327 NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
JBrowse link
G Syn1 synapsin I affects response to substance
multiple interactions
increases response to substance
increases expression
ISO
EXP
SYN1 protein affects the susceptibility to 4-Aminopyridine
[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein; ciproxifan inhibits the reaction [4-Aminopyridine results in increased expression of SYN1 protein modified form]; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein]
SYN1 results in increased susceptibility to 4-Aminopyridine
CTD PMID:22759588 PMID:28132918 PMID:33621091 NCBI chr  X:1,172,208...1,227,400
Ensembl chr  X:1,172,208...1,227,396
JBrowse link
G Traf2 Tnf receptor-associated factor 2 increases expression EXP 4-Aminopyridine results in increased expression of TRAF2 mRNA CTD PMID:24378259 NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
JBrowse link
carglumic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atg5 autophagy related 5 multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of ATG5 mRNA] CTD PMID:31369747 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
JBrowse link
G Becn1 beclin 1 multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of BECN1 mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of BECN1 protein] CTD PMID:31369747 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B protein] CTD PMID:31369747 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in increased expression of SQSTM1 mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in increased expression of SQSTM1 protein] CTD PMID:31369747 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
JBrowse link
ivacaftor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 increases activity
multiple interactions
EXP ivacaftor results in increased activity of ABCB11 protein mutant form
ivacaftor inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]
CTD PMID:36142670 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions
increases activity
ISO [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; [ivacaftor results in increased activity of CFTR protein mutant form] which affects the transport of Sodium; [ivacaftor results in increased activity of CFTR protein mutant form] which results in increased secretion of Chlorides; ivacaftor inhibits the reaction [Vehicle Emissions results in decreased activity of CFTR protein]
ivacaftor results in increased activity of CFTR protein; ivacaftor results in increased activity of CFTR protein mutant form
CTD PMID:19846789 PMID:21083385 PMID:21602569 PMID:32374624 PMID:34601066 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
ixazomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Lat2 linker for activation of T cells family, member 2 multiple interactions ISO ixazomib inhibits the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein]; ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein] CTD PMID:23001822 NCBI chr12:22,104,173...22,118,294
Ensembl chr12:22,104,219...22,118,288
JBrowse link
G Zfand2a zinc finger AN1-type containing 2A increases expression ISO ixazomib results in increased expression of ZFAND2A protein CTD PMID:31540997 NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677
JBrowse link
lenvatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atp5f1a ATP synthase F1 subunit alpha affects expression EXP lenvatinib affects the expression of ATP5F1A protein CTD PMID:34019861 NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
JBrowse link
G Cat catalase decreases expression EXP lenvatinib results in decreased expression of CAT mRNA CTD PMID:34019861 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A affects expression EXP lenvatinib affects the expression of CDKN1A protein CTD PMID:34019861 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression EXP lenvatinib results in decreased expression of CPT1A mRNA CTD PMID:35788046 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Cpt1b carnitine palmitoyltransferase 1B decreases expression EXP
ISO
lenvatinib results in decreased expression of CPT1B mRNA; lenvatinib results in decreased expression of CPT1B protein CTD PMID:35788046 NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression EXP
ISO
lenvatinib results in decreased expression of CPT2 mRNA; lenvatinib results in decreased expression of CPT2 protein CTD PMID:35788046 NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
JBrowse link
G Dnm1l dynamin 1-like increases expression EXP lenvatinib results in increased expression of DNM1L mRNA CTD PMID:34019861 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
JBrowse link
G Fis1 fission, mitochondrial 1 increases expression EXP lenvatinib results in increased expression of FIS1 mRNA CTD PMID:34019861 NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
JBrowse link
G Lonp1 lon peptidase 1, mitochondrial decreases expression EXP lenvatinib results in decreased expression of LONP1 protein CTD PMID:34019861 NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 increases expression EXP lenvatinib results in increased expression of MAP3K5 mRNA CTD PMID:34019861 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases expression EXP lenvatinib results in increased expression of MAPK8 mRNA CTD PMID:34019861 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mfn1 mitofusin 1 affects expression EXP lenvatinib affects the expression of MFN1 mRNA CTD PMID:34019861 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
JBrowse link
G Mfn2 mitofusin 2 affects expression EXP lenvatinib affects the expression of MFN2 mRNA CTD PMID:34019861 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I affects expression
decreases expression
EXP lenvatinib affects the expression of COX1 protein
lenvatinib results in decreased expression of COX1 protein
CTD PMID:34019861 PMID:35788046 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 affects expression EXP lenvatinib affects the expression of NDUFB8 protein CTD PMID:34019861 NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 decreases expression EXP lenvatinib results in decreased expression of NFE2L2 mRNA CTD PMID:34019861 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nrf1 nuclear respiratory factor 1 affects expression EXP lenvatinib affects the expression of NRF1 mRNA CTD PMID:34019861 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase increases expression EXP lenvatinib results in increased expression of OPA1 mRNA CTD PMID:34019861 NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B decreases expression EXP lenvatinib results in decreased expression of SDHB protein CTD PMID:34019861 PMID:35788046 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
JBrowse link
G Slc22a5 solute carrier family 22 member 5 decreases expression ISO
EXP
lenvatinib results in decreased expression of SLC22A5 protein
lenvatinib results in decreased expression of SLC22A5 mRNA; lenvatinib results in decreased expression of SLC22A5 protein
CTD PMID:35788046 NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
JBrowse link
G Slc25a20 solute carrier family 25 member 20 decreases expression ISO
EXP
lenvatinib results in decreased expression of SLC25A20 protein
lenvatinib results in decreased expression of SLC25A20 mRNA; lenvatinib results in decreased expression of SLC25A20 protein
CTD PMID:35788046 NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP lenvatinib results in increased expression of SOD2 mRNA CTD PMID:34019861 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Ucp2 uncoupling protein 2 decreases expression EXP lenvatinib results in decreased expression of UCP2 mRNA; lenvatinib results in decreased expression of UCP2 protein CTD PMID:34019861 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
JBrowse link
G Uqcrc2 ubiquinol cytochrome c reductase core protein 2 affects expression
decreases expression
EXP lenvatinib affects the expression of UQCRC2 protein
lenvatinib results in decreased expression of UQCRC2 protein
CTD PMID:34019861 PMID:35788046 NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
JBrowse link
lumacaftor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Capn1 calpain 1 multiple interactions ISO CAPN1 protein affects the reaction [lumacaftor binds to CFTR protein mutant form] CTD PMID:31324722 NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions
affects folding
ISO [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; calpain inhibitor 2 promotes the reaction [lumacaftor binds to and affects the folding of CFTR protein mutant form]; CAPN1 protein affects the reaction [lumacaftor binds to CFTR protein mutant form]; lumacaftor binds to and affects the folding of CFTR protein mutant form
lumacaftor affects the folding of CFTR protein mutant form
CTD PMID:31324722 PMID:32374624 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
macitentan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A decreases expression ISO macitentan results in decreased expression of ABCB1 mRNA CTD PMID:28369585 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression ISO macitentan results in decreased expression of ABCC2 mRNA CTD PMID:28369585 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 decreases expression ISO macitentan results in decreased expression of ABCC3 mRNA CTD PMID:28369585 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
JBrowse link
G Slc10a1 solute carrier family 10 member 1 decreases expression ISO macitentan results in decreased expression of SLC10A1 mRNA CTD PMID:28369585 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
JBrowse link
rifaximin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases expression
ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ABCB1A mRNA
rifaximin results in increased expression of ABCB1 mRNA
CTD PMID:21141967 PMID:22790967 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ACTA2 mRNA CTD PMID:22790967 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Apoa4 apolipoprotein A4 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of APOA4 mRNA CTD PMID:22790967 NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein] CTD PMID:21599020 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Cd36 CD36 molecule multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein CTD PMID:22790967 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
JBrowse link
G Cfd complement factor D multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mRNA CTD PMID:22790967 NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CIDEC mRNA CTD PMID:22790967 NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of COL1A1 mRNA CTD PMID:22790967 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression ISO Rifaximin results in increased expression of CYP3A4 mRNA CTD PMID:21141967 PMID:27506419 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7A1 protein CTD PMID:22790967 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7B1 protein CTD PMID:22790967 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of DGAT2 mRNA CTD PMID:22790967 NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
JBrowse link
G Fabp2 fatty acid binding protein 2 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of FABP2 protein CTD PMID:22790967 NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
JBrowse link
G Ifng interferon gamma multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein] CTD PMID:21599020 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il10 interleukin 10 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of IL10 protein CTD PMID:21599020 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Lta lymphotoxin alpha multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of LTA mRNA CTD PMID:22790967 NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein] CTD PMID:21599020 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of NR1H4 protein CTD PMID:22790967 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases activity
increases expression
increases response to substance
ISO 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; 4,4'-hexafluorisopropylidene diphenol metabolite inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased abundance of Triglycerides; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ABCB1A mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ACTA2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of APOA4 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CD36 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CFD mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CIDEC mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of COL1A1 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7A1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7B1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of DGAT2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of FABP2 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of LTA mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of NR1H4 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of PPARG mRNA; [Rifaximin binds to and results in increased activity of NR1I2 protein] which results in decreased susceptibility to Trinitrobenzenesulfonic Acid; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; Rifaximin binds to and results in increased activity of NR1I2 protein
[Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
rifaximin results in increased expression of NR1I2 mRNA
NR1I2 results in increased susceptibility to rifaximin
CTD PMID:21599020 PMID:22291955 PMID:22790967 PMID:27506419 PMID:30408883 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of PPARG mRNA CTD PMID:22790967 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of TGFB1 protein CTD PMID:21599020 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] CTD PMID:21599020 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
torasemide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen increases expression EXP Torsemide results in increased expression of AGT protein modified form CTD PMID:18154949 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Cyp11b3 cytochrome P450, family 11, subfamily b, polypeptide 3 affects expression EXP Torsemide affects the expression of CYP11B2 protein CTD PMID:18001696 NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 affects metabolic processing EXP CYP2C11 protein affects the metabolism of Torsemide CTD PMID:15890479 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases metabolic processing
multiple interactions
ISO CYP2C8 protein results in increased metabolism of Torsemide
Torsemide inhibits the reaction [Amiodarone results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Fluoxetine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Nortriptyline results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Phenelzine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein]
CTD PMID:15304522
G Nppa natriuretic peptide A decreases expression EXP Torsemide results in decreased expression of NPPA protein CTD PMID:18154949 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions EXP Torsemide inhibits the reaction [Aldosterone binds to NR3C2 protein] CTD PMID:7954537 NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
JBrowse link
G Ren renin increases expression EXP Torsemide results in increased expression of REN protein CTD PMID:7954537 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G Slc12a2 solute carrier family 12 member 2 decreases activity
multiple interactions
ISO Torsemide results in decreased activity of SLC12A2 protein
Torsemide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium]
CTD PMID:29959396 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases expression
affects expression
EXP Torsemide results in decreased expression of TGFB1 protein
Torsemide affects the expression of TGFB1 protein
CTD PMID:18001696 PMID:18154949 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19838
    role 19810
      application 19679
        pharmaceutical 19495
          drug 19520
            orphan drug 100
              4-aminopyridine + 43
              ACT-333679 + 0
              Orkambi 0
              carglumic acid 4
              isavuconazole 0
              isavuconazonium sulfate 0
              ivacaftor + 2
              ixazomib + 2
              ixazomib citrate 0
              lenvatinib 24
              lenvatinib mesylate 0
              lumacaftor + 2
              macitentan 4
              rifaximin 22
              selexipag 0
              sodium phenylbutyrate 0
              uridine triacetate 0
paths to the root